[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100607545":3},{"organization":4,"outcomesModule":7,"designInfo":56,"detailedDescription":17,"studyPopulation":17,"armGroups":62,"interventions":68,"overallOfficials":17,"centralContacts":74,"locations":84,"responsibleParty":106,"collaborators":17,"id":108,"slug":17,"hasResults":109,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":17,"eligibilityCriteria":113,"healthyVolunteers":109,"sex":114,"minAge":115,"maxAge":116,"enrollmentInfo":117,"targetDuration":17,"studyType":120,"phases":121,"briefSummary":123,"conditions":124,"keywords":17,"overallStatus":87,"whyStopped":17,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":135},{"fullName":5,"class":6},"Jiangsu HengRui Medicine Co., Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":24,"otherOutcomes":17},[9,13,15,19,21],{"measure":10,"description":11,"timeFrame":12},"Incidence and severity of adverse events (AEs).","Graded as per CTCAE v5.0.","From the screening period to 30 days after the last dose.",{"measure":14,"description":11,"timeFrame":12},"Incidence and severity of serious adverse events (SAEs).",{"measure":16,"description":17,"timeFrame":18},"Dose-limiting toxicity (DLT).",null,"From Day 1 to Day 21.",{"measure":20,"description":17,"timeFrame":18},"Maximum tolerated dose (MTD).",{"measure":22,"description":17,"timeFrame":23},"Recommended Phase II Dose (RP2D).","24 months.",[25,28,30,32,34,36,38,40,42,44,46,48,50,52,54],{"measure":26,"description":17,"timeFrame":27},"Maximum plasma concentration (Cmax).","About 24 months.",{"measure":29,"description":17,"timeFrame":27},"The time to maximum concentration (Tmax).",{"measure":31,"description":17,"timeFrame":27},"Area under concentration-time curve from time 0 to the last measurable concentration time point t (AUC0-t).",{"measure":33,"description":17,"timeFrame":27},"Area under concentration-time curve from time 0 to infinity (AUC 0-∞).",{"measure":35,"description":17,"timeFrame":27},"Apparent volume of distribution (Vz\u002FF).",{"measure":37,"description":17,"timeFrame":27},"Elimination half-life (t1\u002F2).",{"measure":39,"description":17,"timeFrame":27},"Apparent clearance (CL\u002FF).",{"measure":41,"description":17,"timeFrame":27},"Minimum concentration at steady state (Cmin, ss).",{"measure":43,"description":17,"timeFrame":27},"Area under the blood concentration-time curve at steady state (AUCss).",{"measure":45,"description":17,"timeFrame":27},"Accumulation ratio (Rac).",{"measure":47,"description":17,"timeFrame":27},"Objective response rate (ORR).",{"measure":49,"description":17,"timeFrame":27},"Duration of response (DoR).",{"measure":51,"description":17,"timeFrame":27},"Disease control rate (DCR).",{"measure":53,"description":17,"timeFrame":27},"Progression-free survival (PFS).",{"measure":55,"description":17,"timeFrame":27},"Overall survival (OS).",{"allocation":57,"interventionModel":58,"interventionModelDescription":17,"primaryPurpose":59,"observationalModel":17,"timePerspective":17,"maskingInfo":60},"NA","SINGLE_GROUP","TREATMENT",{"masking":61,"maskingDescription":17,"whoMasked":17},"NONE",[63],{"label":64,"type":65,"description":17,"interventionNames":66},"HRS-2329 Group","EXPERIMENTAL",[67],"Drug: HRS-2329 Tablet",[69],{"type":70,"name":71,"description":72,"armGroupLabels":73,"otherNames":17},"DRUG","HRS-2329 Tablet","Oral HRS-2329 tablet.",[64],[75,80],{"name":76,"role":77,"phone":78,"phoneExt":17,"email":79},"Rongfu Mao","CONTACT","+86 021-61053363","rongfu.mao@hengrui.com",{"name":81,"role":77,"phone":82,"phoneExt":17,"email":83},"Jizhao Li","+86-021-61053363","jizhao.li.jl565@hengrui.com",[85],{"facility":86,"status":87,"city":88,"state":89,"zip":90,"country":91,"countryCode":92,"cosmosGeoPoint":93,"geoPoint":98,"contacts":99},"Tianjin Medical University Cancer Institute and Hospital","RECRUITING","Tianjin","Tianjin Municipality","300181","China","CN",{"type":94,"coordinates":95},"Point",[96,97],117.17667,39.14222,{"lat":97,"lon":96},[100,104],{"name":101,"role":77,"phone":102,"phoneExt":17,"email":103},"Jihui Hao","+86-022-23340123","haojihui@tjmuch.com",{"name":101,"role":105,"phone":17,"phoneExt":17,"email":17},"PRINCIPAL_INVESTIGATOR",{"type":107,"investigatorFullName":17,"investigatorTitle":17,"investigatorAffiliation":17,"oldNameTitle":17,"oldOrganization":17},"SPONSOR","100607545",false,"NCT07189949","A Study of HRS-2329 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications","A Phase I Study of HRS-2329 Evaluating Safety, Tolerability, and Pharmacokinetics in Subjects With Advanced Solid Tumors Harboring RAS Mutations or Amplifications","Inclusion Criteria:\n\n1. Have fully understood this study and are willing to sign the ICF, with good compliance and cooperation in follow-up;\n2. Aged between 18-75 years old;\n3. Participants with histologically\u002Fcytologically confirmed advanced solid tumors who have been previously tested or are confirmed by the central laboratory to harbor RAS mutations or amplifications and have failed standard treatment;\n4. ECOG performance status (PS) score of 0 or 1;\n5. Life expectancy \\> 3 months;\n6. At least one measurable lesion per RECIST v1.1;\n7. Adequate organ function.\n\nExclusion Criteria:\n\n1. Toxicity (e.g., gastrointestinal reaction and skin toxicity) from prior anti-tumor treatment has not recovered to Grade ≤ 1 or a level specified in the inclusion\u002Fexclusion criteria;\n2. Presence of central nervous system (CNS) metastases;\n3. Participants with gastrointestinal diseases that affect drug administration\u002Fabsorption;\n4. Participants who have undergone major surgery other than diagnosis or biopsy within 28 days before the first dose, or are expected to undergo major surgery during the study period;\n5. Presence of serious pulmonary diseases;\n6. Active tuberculosis or a history of active tuberculosis infection within 48 weeks prior to screening, regardless of whether they have been treated;\n7. Active or persistent gastrointestinal bleeding within 6 months prior to screening;\n8. History of allogeneic bone marrow or solid organ transplantation;\n9. History of deep vein thrombosis or pulmonary embolism within 6 months prior to screening;\n10. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring clinical intervention;\n11. Positive human immunodeficiency virus (HIV) (HIV1\u002F2 antibodies), active chronic hepatitis B, or active hepatitis C (positive HCV antibody and positive HCV RNA);\n12. Known history of hypersensitivity to any component of the drug product to be used in the study.","ALL","18 Years","75 Years",{"count":118,"type":119},120,"ESTIMATED","INTERVENTIONAL",[122],"PHASE1","This is an open-label, multi-center phase I clinical study to evaluate the safety, tolerability, and pharmacokinetics of HRS-2329 in participants with advanced solid tumors harboring RAS mutations or amplifications.",[125],"Advanced Solid Tumors Harboring RAS Mutations or Amplifications","2026-03-05",{"date":128,"type":129},"2026-03-06","ACTUAL",{"date":131,"type":129},"2025-10-16",{"date":133,"type":119},"2028-12",{"name":5,"class":6},1]